What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Khavinson bioregulator tetrapeptide (Ala-Glu-Asp-Leu, AEDL)
PeptideXpo buyer fit
This PeptideXpo page is intentionally positioned for distributors, OEM buyers, and procurement teams comparing Bronchogen inside a wider peptide catalog. It is not trying to be the deepest single-molecule monograph; the differentiated intent is assortment planning, export-ready documentation, fill-size comparison, and whether this SKU belongs in a broader buyer program.
Overview
Bronchogen is a Khavinson-class short-peptide bioregulator with the sequence Ala-Glu-Asp-Leu (AEDL), targeting respiratory-tissue regulatory pathways within the broader Khavinson bioregulator framework. The molecule was developed at the St. Petersburg Institute of Bioregulation and Gerontology as the respiratory-tissue member of the Khavinson short-peptide family, alongside Cortagen (cerebral cortex, AEDP), Pinealon (cognitive, EDR), Vesugen (vascular, KED), Cardiogen (cardiovascular), and others. The shared hypothesis is that short tissue-specific peptide fragments isolated from animal tissues act as endogenous bioregulators of cell-cycle and gene-expression programs in their target tissues; Bronchogen specifically is positioned in the Russian-school research literature as a regulatory peptide for bronchial epithelium and respiratory-tissue maintenance. PeptideXpo supplies Bronchogen as a lyophilized 20 mg vial at ≥99.0% HPLC purity. CAS is not consistently registered across suppliers for the Khavinson bioregulator class, so identity is established via sequence verification by LC-MS/MS plus mass-spec confirmation of the AEDL tetrapeptide on every batch COA, particularly important because the four members of the Khavinson tetrapeptide family (AEDG / AEDL / AEDP / KED) are close in mass and require explicit sequencing to disambiguate.
Who buys this, and why
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Primary buyer fit: academic and contract research laboratories.
Specifications
Documentation available on request
Regulatory note
Khavinson bioregulator (Russian scientific lineage); CAS commonly not registered. Confirm AEDL sequence and identity per batch COA, disambiguation from sibling tetrapeptides (AEDG / AEDP / KED) in the family is essential since the masses are close.
Frequently asked questions
The Khavinson tetrapeptide family shares an Ala-Glu-Asp tripeptide core (AED-) and differs only in the fourth C-terminal residue: Bronchogen is AEDL (with Leucine), Epitalon is AEDG (Glycine), Cortagen is AEDP (Proline). The molecular weights are close (Bronchogen ≈432 Da, Epitalon ≈390 Da, Cortagen ≈400 Da, all within a 50 Da range), which means mass spec alone is insufficient to disambiguate, the molecules can be confused on the COA if only mass is reported. LC-MS/MS sequence verification covering the full b- and y-ion ladder is the definitive identity check. Buyers ordering any single Khavinson tetrapeptide should request explicit sequence-verification data on the batch COA, especially when sourcing from a new supplier.
Khavinson-school publications on Bronchogen focus on respiratory-epithelium gene-expression effects in animal models of chronic bronchopulmonary disease and aging-related respiratory decline. The reported readouts include modulation of bronchial epithelial cell proliferation markers, antioxidant-enzyme expression in respiratory tissue, and improvements in pulmonary function metrics in aged-rat models. As with the rest of the Khavinson framework, the evidence base is concentrated in Russian-language journals and translated proceedings from the St. Petersburg Institute of Bioregulation and Gerontology, Western peer-reviewed coverage is limited and the mechanism-of-action data has not been independently replicated outside the Khavinson research lineage at the rigor level Western evidence-based-medicine frameworks expect. Buyers working with Bronchogen should reference the Khavinson primary literature for protocol design and treat the molecule as an investigational research tool.
Published Khavinson-school Bronchogen protocols use both intranasal and intramuscular administration routes. The intranasal route is the more commonly used in respiratory-focused research because direct delivery to the airway epithelium maximizes tissue exposure at the target organ. The intramuscular route produces systemic exposure that is appropriate for studies examining whole-organism effects rather than direct airway-tissue interaction. Working dilutions for intranasal preparation should use isotonic saline as the vehicle with neutral pH (5.5-7.0); benzalkonium chloride and similar quaternary-ammonium preservatives should be avoided in intranasal peptide formulations because they interact with short peptide sequences.
Related peptides
Khavinson cardiovascular short-peptide bioregulator
4-mer
Khavinson cortical bioregulator tetrapeptide (Ala-Glu-Asp-Pro, AEDP)
3-mer
Khavinson neuroprotective tripeptide (Glu-Asp-Arg, EDR)
